

**REMARKS**

In the final Office Action of March 23, 2011, the Examiner identified claims 31, 32, 34, 35, 40 and 41 as being allowed. With this amendment, all but one of the non-allowed claims are canceled without prejudice or disclaimer of the subject matter thereof. Claim 36 directed to specific, isolated nucleic acid sequences has been retained and amended to be an independent claim. It is believed to be allowable as it no longer depends on a non-allowed claim.

Applicant does not believe that any fee is due in connection with this filing. If, however, Applicant does owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **19-0365**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or repay such overpayment to Deposit Account No. **19-0365**.

Should the Examiner have any additional questions or concerns, he is invited to telephone Applicant's attorney at the number below.

Respectfully submitted,

/William M. BLACKSTONE/  
Registration No. 29,772

William M. Blackstone  
Registration No. 29,772

Dated: **May 19, 2011**  
Merck & Co., Inc.  
Intellectual Property-Animal Health/Intervet  
Law Dept. K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Telephone: (410) 464-0491  
Facsimile: (908) 298-5388